Study from MD Anderson and Ohio State finds B cell receptor inhibitor causes remission in chronic lymphocytic leukemia:
NCI Cancer Center News
A new, targeted approach to treating chronic lymphocytic leukemia (CLL) has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology… The agent, called PCI-32765, is the first drug designed to target Bruton’s tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.